argenx (NASDAQ:ARGX) was downgraded by Kepler Capital Markets from a “buy” rating to a “hold” rating in a research report issued on Friday, The Fly reports.
Other research analysts have also issued reports about the stock. Zacks Investment Research raised shares of argenx from a “hold” rating to a “buy” rating and set a $284.00 target price for the company in a research note on Wednesday. HC Wainwright started coverage on shares of argenx in a research note on Wednesday. They set a “neutral” rating and a $272.00 target price for the company. Robert W. Baird boosted their target price on shares of argenx from $170.00 to $235.00 and gave the company an “outperform” rating in a research note on Wednesday, May 27th. Cowen reissued a “buy” rating on shares of argenx in a research note on Wednesday, June 17th. Finally, Stifel Nicolaus reissued a “buy” rating and set a $253.00 target price on shares of argenx in a research note on Thursday. Five research analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the company. The stock currently has a consensus rating of “Buy” and an average target price of $227.18.
Shares of NASDAQ:ARGX opened at $230.13 on Friday. argenx has a fifty-two week low of $103.75 and a fifty-two week high of $272.74. The firm has a 50-day simple moving average of $237.95 and a 200 day simple moving average of $174.99. The company has a market cap of $10.82 billion, a PE ratio of -48.65 and a beta of 1.22.
argenx (NASDAQ:ARGX) last announced its quarterly earnings data on Thursday, May 14th. The company reported ($1.87) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.72) by ($0.15). The company had revenue of $21.15 million for the quarter, compared to analyst estimates of $18.08 million. As a group, analysts expect that argenx will post -10.39 earnings per share for the current fiscal year.
Hedge funds have recently added to or reduced their stakes in the stock. Arden Trust Co acquired a new stake in argenx during the first quarter valued at approximately $86,000. SG Americas Securities LLC acquired a new stake in argenx during the second quarter valued at approximately $156,000. Marshall Wace LLP acquired a new stake in argenx during the first quarter valued at approximately $121,000. FNY Investment Advisers LLC acquired a new stake in argenx during the second quarter valued at approximately $225,000. Finally, Tower Research Capital LLC TRC lifted its stake in argenx by 128.5% during the first quarter. Tower Research Capital LLC TRC now owns 1,131 shares of the company’s stock valued at $149,000 after purchasing an additional 636 shares during the last quarter. 49.64% of the stock is owned by institutional investors and hedge funds.
argenx Company Profile
argenx SE, a clinical-stage biopharmaceutical company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases and cancer. The company's lead product candidates include ARGX-113 that completed Phase 2 clinical trials for the treatment of autoimmune diseases, including myasthenia gravis, immune thrombocytopenia, and pemphigus vulgaris; and ARGX-110, which is in Phase 1/2 clinical trials for the treatment of T-cell lymphoma, acute myeloid leukemia, and myelodysplastic syndrome.
Receive News & Ratings for argenx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for argenx and related companies with MarketBeat.com's FREE daily email newsletter.